High-Dose IV Iron Safely and Effectively Treats IBD-Associated Anemia Regardless of Inflammatory Activity: Real-Life Evidence from Germany

A study involving 421 patients with Crohn’s disease or ulcerative colitis in Germany demonstrated that high-dose intravenous (IV) iron therapy is effective and safe for treating IBD-associated anaemia, regardless of inflammatory activity. Patients received either iron isomaltoside or ferric carboxymaltose, with a mean cumulative dose of approximately 1,200 mg over 12-16 weeks. The treatment led to significant improvements in haemoglobin levels, ferritin, and transferrin saturation, and reduced C-reactive protein (CRP) levels, particularly in those with elevated baseline CRP. Clinical disease activity and IBD-related symptoms also improved, with no evidence of worsening disease activity. The study supports high-dose IV iron as a standard care for IBD-associated anaemia.